![]() |
Trials |
BORTEM-17: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide a phase IB/II studyCancer type: Glioblastoma Phase: I/II Principal Investigator: Golpen Dorota Country: NO Keywords: Norway, Bergen, Glioblastoma, Bortezomib and Telozolomide Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03643549?cond=Glioblastoma&cntry=NO&rank=1 |